Targeting T cells to tumor cells using bispecific antibodies

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 385-392

  Frankel, Stanley R ^a,b   Baeuerle, Patrick A ^c  

^a Amgen   (United States)

^b Milstein Hospital   (United States)

^c Amgen Research GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 211; AMG 212; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BLINATUMOMAB; CARCINOEMBRYONIC ANTIGEN; CATUMAXOMAB; CD19 ANTIGEN; CD69 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; RECOMBINANT ANTIBODY; SOLITOMAB; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMYLASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILL; CONTINUOUS INFUSION; CYTOKINE RELEASE; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; GASTROINTESTINAL CARCINOMA; HUMAN; HYPOALBUMINEMIA; LARGE CELL LYMPHOMA; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER METASTASIS; LYMPHOCYTOPENIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; SEIZURE; SIDE EFFECT; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR CELL; VOMITING;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84878931351     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.03.029     Document Type: Review

References (58)

1. Gao J., Bernatchez C., Sharma P., Radvanyi L.G., Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 2013, 34:90-98.
2. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12:298-306.
3. Boniface J.D., Poschke I., Mao Y., Kiessling R. Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 2012, 131:129-139.
4. Stewart T., Smyth M. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metast Rev 2011, 30:125-140.
5. Whiteside T.L. What are regulatory T cells (Treg) regulating in cancer and why?. Semin Cancer Biol 2012, 22:327-334.
6. Pardoll D.M. Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012, 13:1129-1132.
7. Baeuerle P.A., Zugmaier G., Ruttinger D. Bispecific T cell engager for cancer therapy. Bispecific Antibodies 2011, 273-287. Springer-Verlag. R.E. Kontermann (Ed.).
8. Riethmuller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012, 12:12.
9. Nagorsen D., Kufer P., Baeuerle P.A., Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012, 136:334-342.
10. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
11. Viardot A., Goebeler M., Noppeney R., Krause S.W., Kallert S., Ferstl B., Mackensen A., Rupertus K., Soekler M., Kanz L., et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. Blood 2011, 118:711-712.
12. 2/d is tolerable and highly effective. ASH Annu Meet Abst 2010, 116:2880.
13. Goebeler M., Viardot A., Noppeney R., Krause S., Mackensen A., Rupertus K., Kanz L., Knop S., Topp M., Scheele J., et al. Blinatumomab (CD3/CD19 BITE antibody) results in a high response rate in patients with relapsed non-Hodgkin lymphoma (NHL) including MCL and DLBCL. Ann Oncol (ICML) 2011, 22:105. (abstract 068).
14. Topp M.S., Gökbuget N., Zugmaier G., Degenhard E., Goebeler M.-E., Klinger M., Neumann S.A., Horst H.A., Raff T., Viardot A., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012, 120:5185-5187.
15. Topp M.S., Kufer P., Gökbuget N., Goebeler M., Klinger M., Neumann S., Horst H.-A., Raff T., Viardot A., Schmid M., et al. Targeted therapy with the T-Cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.
16. Topp M.S., Goekbuget N., Zugmaier G., Viardot A., Stelljes M., Neumann S., Horst H.A., Reichle A., Marks R., Faul C., et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). ASH Annu Meet Abst 2012, 120:670.
17. Klinger M., Brandl C., Zugmaier G., Hijazi Y., Bargou R.C., Topp M.S., Gokbuget N., Neumann S., Goebeler M., Viardot A., et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012, 119:6226-6233.
18. Patriarca C., Macchi R.M., Marschner A.K., Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012, 38:68-75.
19. Amann M., Brischwein K., Lutterbuese P., Parr L., Petersen L., Lorenczewski G., Krinner E., Bruckmeier S., Lippold S., Kischel R., et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008, 68:143-151.
20. Heiss M.M., Murawa P., Koralewski P., Kutarska E., Kolesnik O.O., Ivanchenko V.V., Dudnichenko A.S., Aleknaviciene B., Razbadauskas A., Gore M., et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010, 127:2209-2221.
21. Haas C., Krinner E., Brischwein K., Hoffmann P., Lutterbuse R., Schlereth B., Kufer P., Baeuerle P.A. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009, 214:441-453.
22. Cioffi M., Dorado J., Baeuerle P.A., Heeschen C. EpCAM/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012, 18:465-474.
23. Herrmann I., Baeuerle P.A., Friedrich M., Murr A., Filusch S., Ruttinger D., Majdoub M.W., Sharma S., Kufer P., Raum T., et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS ONE 2010, 5:e13474.
24. Amann M., D'Argouges S., Lorenczewski G., Brischwein K., Kischel R., Lutterbuese R., Mangold S., Rau D., Volkland J., Pflanz S., et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009, 32:452-464.
25. Amann M., Friedrich M., Lutterbuese P., Vieser E., Lorenczewski G., Petersen L., Brischwein K., Kufer P., Kischel R., Baeuerle P.A., et al. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunol Immunother 2009, 58:95-109.
26. Fiedler W.M.W.M., Kebenko M., Goebeler M.-E., Ritter B., Quaas A., Vieser E., Hijazi Y., Patzak I., Friedrich M., Kufer P., Frankel S., Seggewiss-Bernhardt R., Kaubitzsch S. A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2012, 30(suppl; abstr 2504). 2012 ASCO Annual Meeting Proceeding.
27. Fiedler W.M., Ritter B., Seggewiss R., Bokemeyer C., Fettes P., Klinger M., Vieser E., Ruettinger D., Kaubitzsch S., Wolf M. Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. J Clin Oncol (Meeting Abstracts) 2010, 28(15s (suppl; abstr 2573)).
28. Turriziani M., Fantini M., Benvenuto M., Izzi V., Masuelli L., Sacchetti P., Modesti A., Bei R. Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov 2012, 7:265-296.
29. Dallas M.R., Liu G., Chen W.-C., Thomas S.N., Wirtz D., Huso D.L., Konstantopoulos K. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J 2012, 26:2648-2656.
30. Peng L., Oberst M.D., Huang J., Brohawn P., Morehouse C., Lekstrom K., Baeuerle P.A., Wu H., Yao Y., Coats S.R., et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS ONE 2012, 7:e36412.
31. Lutterbuese R., Raum T., Kischel R., Lutterbuese P., Schlereth B., Schaller E., Mangold S., Rau D., Meier P., Kiener P.A., et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009, 32:341-352.
32. Osada T., Hsu D., Hammond S., Hobeika A., Devi G., Clay T.M., Lyerly H.K., Morse M.A. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 2010, 102:124-133.
33. Rajasekaran A.K., Anilkumar G., Christiansen J.J. Is prostate-specific membrane antigen a multifunctional protein?. Am J Physiol Cell Physiol 2005, 288:C975-C981.
34. Friedrich M., Raum T., Lutterbuese R., Voelkel M., Deegen P., Rau D., Kischel R., Hoffmann P., Brandl C., Schuhmacher J., et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012, 11:2664-2673.
35. Friedrich M., Deegen P., Voelkel M., Wahl J.J.S., Steinkem W., Zopf D., Harris R.B., Baeuerle P.A., Kufer P., et al. Abstract 3526: subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice. Cancer Res 2012, 72(Suppl 1).
36. Aigner M., Feulner J., Schaffer S., Kischel R., Kufer P., Schneider K., Henn A., Rattel B., Friedrich M., Baeuerle P.A., et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE[reg] antibody construct. Leukemia 2012, 10.1038/leu.2012.341.
37. Lutterbuese R., Raum T., Kischel R., Hoffmann P., Mangold S., Rattel B., Friedrich M., Thomas O., Lorenczewski G., Rau D., et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 2010, 107:12605-12610.
38. Bluemel C., Hausmann S., Fluhr P., Sriskandarajah M., Stallcup W.B., Baeuerle P.A., Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010, 59:1197-1209.
39. Torisu-Itakura H., Schoellhammer H.F., Sim M.S., Irie R.F., Hausmann S., Raum T., Baeuerle P.A., Morton D.L. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother 2011, 34:597-605.
40. Baeuerle P.A., Raum T. Resurgence of bispecific antibodies. Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges 2013, 529-543. John Wiley & Sons. edn 1. S.R. Schmidt (Ed.).
41. Baeuerle P.A., Itin C. Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer. Curr Pharm Biotechnol 2012, 13:1399-1408.
42. Groth A., Salnikov A.V., Ottinger S., Gladkich J., Liu L., Kallifatidis G., Salnikova O., Ryschich E., Giese N., Giese T., et al. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAM×CD3 bispecific antibody for tumor targeting. Clin Cancer Res 2012, 18:1028-1038.
43. Feldmann A., Arndt C., Töpfer K., Stamova S., Krone F., Cartellieri M., Koristka S., Michalk I., Lindemann D., Schmitz M., et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012, 189:3249-3259.
44. Fortmüller K., Alt K., Gierschner D., Wolf P., Baum V., Freudenberg N., Wetterauer U., Elsässer-Beile U., Bühler P. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA×CD3 bispecific single-chain diabody. Prostate 2011, 71:588-596.
45. Sewell T., Hernandez-Hoyos G., Chenault R.A., Wiens J., Kumer J., Natarajan S., McMahan C.J., Algate P.A., Blankenship J.W. 319 anti-PSMA×anti-CD3 bispecific antibody efficiently redirects T cell cytotoxicity in castrate-resistant prostate cancer models. Eur J Cancer 2012, 48(Suppl 6):98.
46. Baum V., Bühler P., Gierschner D., Herchenbach D., Fiala G.J., Schamel W.W.A., Wolf P., Elsässer-Beile U. Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy 2013, 5:27-38.
47. Yamamoto K., Trad A., Baumgart A., Huske L., Lorenzen I., Chalaris A., Grotzinger J., Dechow T., Scheller J., Rose-John S. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 2012, 445:135-144.
48. Choi B.D., Cai M., Bigner D.D., Mehta A.I., Kuan C.T., Sampson J.H. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011, 11:843-853.
49. Kuo S.-R., Wong L., Liu J.-S. Engineering a CD123×CD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Select 2012, 25:561-570.
50. Portner L.M., Schonberg K., Hejazi M., Brunnert D., Neumann F., Galonska L., Reusch U., Little M., Haas R., Uhrberg M. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19×CD3 or CD19×CD16. Cancer Immunol Immunother 2012, 61:1869-1875.
51. Moore P.A., Zhang W., Rainey G.J., Burke S., Li H., Huang L., Gorlatov S., Veri M.C., Aggarwal S., Yang Y., et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011, 117:4542-4551.
52. Cui H., Thomas J.D., Burke T.R., Rader C. Chemically programmed bispecific antibodies that recruit and activate T cells. J Biol Chem 2012, 287:28206-28214.
53. Liddy N., Bossi G., Adams K.J., Lissina A., Mahon T.M., Hassan N.J., Gavarret J., Bianchi F.C., Pumphrey N.J., Ladell K., et al. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012, 18:980-987.
54. McCormack E., Adams K., Hassan N., Kotian A., Lissin N., Sami M., Mujić M., Osdal T., Gjertsen B., Baker D., et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 2012, 1-13.
55. Marr L.A., Gilham D.E., Campbell J.D.M., Fraser A.R. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol 2012, 167:216-225.
56. Shi H., Liu L., Wang Z. Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 2013, 328:191-197.
57. Gilham D.E., Debets R., Pule M., Hawkins R.E., Abken H. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 2012, 18:377-384.
58. Stone J.D., Aggen D.H., Schietinger A., Schreiber H., Kranz D.M. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunol 2012, 1:863-873.